Dr. Danso is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
5900 Lake Wright Dr
Norfolk, VA 23502Phone+1 757-466-8683Fax+1 757-466-8892
Education & Training
Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2002 - 2005
Pennsylvania Hospital of the University of Pennsylvania Health SystemResidency, Internal Medicine, 1999 - 2002
Royal Free Hospital and University College London Medical SchoolClass of 1996
Certifications & Licensure
VA State Medical License 2007 - 2026
FL State Medical License 2005 - 2017
NY State Medical License 2002 - 2007
PA State Medical License 2000 - 2002- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
Clinical Trials
- PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 Mutations Start of enrollment: 2010 Feb 01
- Study of Letrozole With or Without BYL719 or Buparlisib, for the Neoadjuvant Treatment of Postmenopausal Women Start of enrollment: 2014 Mar 11
- A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study) Start of enrollment: 2013 Oct 14
- Join now to see all
Publications & Presentations
PubMed
- 3 citationsNeoadjuvant talazoparib in patients with germline BRCA1/2 mutation-positive, early-stage triple-negative breast cancer: exploration of tumor BRCA mutational status.Melinda L Telli, Jennifer K Litton, J Thaddeus Beck, Jason M Jones, Jay Andersen
Breast Cancer. 2024-09-01 - Systemic Treatment of Patients With Metastatic Breast Cancer: ASCO Resource-Stratified Guideline.Sana Al Sukhun, Sarah Temin, Carlos H Barrios, Nicoleta Zenovia Antone, Yanin Chavarri Guerra
JCO Global Oncology. 2024-01-01 - 3 citationsVERITAC-2: a Phase III study of vepdegestrant, a PROTAC ER degrader, versus fulvestrant in ER+/HER2- advanced breast cancer.Erika P Hamilton, Cynthia Ma, Michelino De Laurentiis, Hiroji Iwata, Sara A Hurvitz
Future Oncology. 2024-01-01
Press Mentions
Year in Review Session Summarizes Important Breast Cancer Takeaways from 2024December 15th, 2024- Special Session Explores Considerations Behind Breast Cancer Drug Approvals, TrialsDecember 15th, 2024
- GHS Sets up Committee to Investigate Death of Supposed Covid-19 PatientAugust 21st, 2021
- Join now to see all
Professional Memberships
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
